ValiCore Blog
Practical pharma compliance writing for QA Heads and QC Managers — Schedule M, CDSCO inspections, 21 CFR Part 11, OOS investigations. No theory dumps.
Paperless Labs: What It Actually Means Beyond Scanning SOPs to PDF
A truly paperless lab captures structured data at the point of work — not just stores digitized copies of paper records. Here's the real distinction, with the concrete cost-savings figure to back it.
Read article
Pharma AI in 2026: Beyond the "AI-Powered" Marketing Claim
Every eQMS vendor now claims "AI-powered." Here's what's actually believable near-term — specific use cases like OOS root-cause suggestion — versus generic hype.
Read article
Laboratory Digital Transformation: Real Cost Savings, Not Just a Buzzword
Paperless labs can yield 25-45% cost savings in chemical QC labs — a specific, checkable figure most digital-transformation content lacks. Here's what actually changes.
Read article
Digital Validation: Why GAMP 5's Risk-Based Model Is Replacing Checklist Validation
GAMP 5 Second Edition's Computer Software Assurance alignment is reshaping validation — critical thinking over exhaustive checklists. Here's what that actually means for a growing lab.
Read article
Excel vs. Compliance Software: An Honest Answer, Not a Blanket "Excel Is Bad"
Excel isn't inherently non-compliant — but as a system of record for GxP data, it consistently fails the same three things auditors check. Here's the nuanced, accurate answer.
Read article
Instrument Qualification (IQ/OQ/PQ): The Evidence Chain Auditors Actually Trace
IQ/OQ/PQ isn't three separate documents — it's one traceable chain from URS through risk assessment to executed evidence. Here's how each stage actually connects to the next.
Read article
Risk Assessment in Pharma: How QRM Became a Named Requirement, Not a Nice-to-Have
Quality Risk Management (QRM) is now formally required under revised Schedule M — not an optional best practice. Here's how real risk assessment differs from a narrative paragraph in an SOP.
Read article
Change Control: Why Every Change Needs a Re-Qualification Question, Not Just a Log Entry
Change control isn't a log of what changed — it's the trigger mechanism for deciding whether re-qualification is required. Here are the specific findings inspectors name most often.
Read article
The CAPA Process: Root Cause, Action, and the Effectiveness Check Most Skip
A CAPA that closes without a documented effectiveness check hasn't actually closed the loop. Here's the real process — Five Whys, corrective vs. preventive action, and the verification step most systems skip.
Read article
OOT Investigation: The Early-Warning Layer Most Labs Skip
Out-of-Trend (OOT) monitoring catches drift before it becomes an OOS failure — but most quality systems treat it as an afterthought rather than its own distinct discipline.
Read article
OOS Investigation: The FDA's Actual Phase 1 / Phase 2 Structure and Timelines
FDA's 2022 OOS guidance (Revision 1) sets specific timeline benchmarks most articles still get wrong. Here's the real Phase 1/Phase 2 branching logic and the exact timelines.
Read article
Calibration SOP: The As-Found/As-Left Detail Most Labs Get Wrong
A calibration SOP that only records the as-left reading can never prove an instrument was in tolerance before adjustment. Here's the specific data structure NABL and GMP auditors actually check.
Read article
WHO GMP Requirements: TRS 986, TRS 1044, and What They Actually Cover
WHO-GMP certification is the gateway to export markets and WHO prequalification. Here's what TRS 986, TRS 1044, and TRS 1052 each cover — and how WHO-GMP relates to Schedule M.
Read article
FDA Audit Preparation: Why Inspection-Readiness Is a Daily State, Not a Sprint
FDA conducted 1,927 facility inspections globally in 2024, with 42% resulting in Warning Letters. Real India-specific cases show what actually goes wrong — and why last-minute prep doesn't work.
Read article
CDSCO Audit Checklist: What Inspectors Check Under Revised Schedule M
CDSCO's 2025-2026 inspection posture is active, with monthly compliance reporting and immediate inspections for manufacturers who missed the extension deadline. Here's the real checklist.
Read article
GAMP 5 Guide: Risk-Based Computer System Validation, Explained
GAMP 5 Second Edition (2022) reshaped how pharma validates software — cloud/SaaS guidance, CSA alignment, and risk-based categorization. Here's what each category actually means, with a worked example.
Read article
ALCOA+ Explained: The Nine Data Integrity Attributes Regulators Actually Check
ALCOA+ is the data integrity framework behind every FDA and WHO inspection finding on record-keeping. Here are all nine attributes, the regulations that codify them, and the single most common violation.
Read article
What Is 21 CFR Part 11? The Audit Trail and E-Signature Rule, Explained
21 CFR Part 11 governs electronic records and signatures for FDA-regulated industries. Here's what §11.10(e) and Subpart C actually require — and why Excel doesn't meet the bar.
Read article
The Schedule M Grace Period Is Over. Is Your Lab Actually Ready for an Inspection?
The one-year grace period for MSME pharma manufacturers to comply with revised Schedule M ended December 31, 2025. CDSCO has directed state regulators to begin inspections. Here's what inspectors actually check, and a 5-question gut check for your QA team.
Read article
Schedule M (Revised 2023) — what Indian pharma labs must do before their next CDSCO inspection
The revised Schedule M became mandatory for Indian pharma manufacturers from January 2024 (large) and January 2026 (MSME). This is the operational checklist your QC lab needs before CDSCO walks in — written for QA Heads, not policy people.
Read article